The SAKURA study is a Phase III, multinational, double-masked trial investigating the safety and efficacy of DE-109 for the treatment of non-infectious uveitis of the posterior segment. DE-109 is a proprietary formulation of sirolimus that is an anti-inflammatory agent. If you have been diagnosed with uveitis of the posterior segment or if you have questions regarding this study, please contact Kate Cernok, PhD at kcernok@santeninc.com.
SAKURA Phase III Study
The SAKURA study is a Phase III, multinational, double-masked trial investigating the safety and efficacy of DE-109 for the treatment of non-infectious uveitis of the posterior segment. DE-109 is a proprietary formulation of sirolimus that is an anti-inflammatory agent. If you have been diagnosed with uveitis of the posterior segment or if you have questionsLearn More
November 13, 2015
Categories
Recent Posts
- 26 Patient Volunteer Leaders Attend the Foundation for Sarcoidosis Research Global Sarcoidosis Clinic Alliance Volunteer Patient Leadership Advanced Training Conference held at Cleveland Clinic
- FSR to Host 30 Volunteer Patient Leaders at Unique In-Person Training at Cleveland Clinic
- 6 Things You Should Know About Clinical Trials
- Tricha Shivas Promoted to Chief of Staff and Strategy at Foundation for Sarcoidosis Research
- Advocating for Improved Access to Oxygen